{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/53607"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/53607","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"A self-assembling coiled-coil peptide platform for antibody-targeted therapeutics","abstract":"Antibody-drug conjugates (ADCs) have revolutionized cancer treatment, yet significant challenges limit their therapeutic potential and hamper their advancement to first-line treatments. Traditional conjugation methods lack stability, site-specificity and spatial control, resulting in heterogeneous products with compromised pharmacokinetics, efficacy, and safety profiles. This thesis presents a platform for advancing ADC technology through developing a novel peptide-based conjugation strategy and expands it to diverse payloads to create safe next-generation therapeutics. We first developed a supramolecular assembly conjugation method based on coiled-coil peptides to generate a robust site-specific ADC. This approach affords modular conjugation of multiple payloads. An ADC created via this platform demonstrated efficacy in human ovarian cancer xenograft model. Next, we developed a gram-scale synthetic scheme of a multifunctional cathepsin B-responsive linker that facilitates controlled drug release from antibodies. This scheme is high-yielding and avoids chromatographic purification, providing a pure product at the gram scale. Building on the coiled-coil conjugation platform, we demonstrated its modularity by expanding beyond traditional cytotoxic payloads to create antibody-enzyme conjugates that leverage enzymatic activity for metastasis reduction. By conjugating DNase to a neutrophil targeting antibody, we ensured enzyme delivery to close proximity of neutrophil extracellular traps, thereby reducing lung metastatic burden in an orthotopic 4T1 metastatic breast cancer model. Finally, we introduced a \"smart\" ADC platform integrating tumor-targeting with novel Regulated Induced Proximity Targeting Chimeras (RIPTACs). This approach overcomes off-target toxicities by requiring both extracellular target recognition and intracellular target recognition, establishing safer, more selective antibody-based therapeutics. Collectively, this work provides a uniform toolbox for ADC engineering and introduces new concepts for designing next-generation antibody conjugates with alternative payloads and mechanisms of action.","abstract_html":"Antibody-drug conjugates (ADCs) have revolutionized cancer treatment, yet significant challenges limit their therapeutic potential and hamper their advancement to first-line treatments. Traditional conjugation methods lack stability, site-specificity and spatial control, resulting in heterogeneous products with compromised pharmacokinetics, efficacy, and safety profiles. This thesis presents a platform for advancing ADC technology through developing a novel peptide-based conjugation strategy and expands it to diverse payloads to create safe next-generation therapeutics. We first developed a supramolecular assembly conjugation method based on coiled-coil peptides to generate a robust site-specific ADC. This approach affords modular conjugation of multiple payloads. An ADC created via this platform demonstrated efficacy in human ovarian cancer xenograft model. Next, we developed a gram-scale synthetic scheme of a multifunctional cathepsin B-responsive linker that facilitates controlled drug release from antibodies. This scheme is high-yielding and avoids chromatographic purification, providing a pure product at the gram scale. Building on the coiled-coil conjugation platform, we demonstrated its modularity by expanding beyond traditional cytotoxic payloads to create antibody-enzyme conjugates that leverage enzymatic activity for metastasis reduction. By conjugating DNase to a neutrophil targeting antibody, we ensured enzyme delivery to close proximity of neutrophil extracellular traps, thereby reducing lung metastatic burden in an orthotopic 4T1 metastatic breast cancer model. Finally, we introduced a &quot;smart&quot; ADC platform integrating tumor-targeting with novel Regulated Induced Proximity Targeting Chimeras (RIPTACs). This approach overcomes off-target toxicities by requiring both extracellular target recognition and intracellular target recognition, establishing safer, more selective antibody-based therapeutics. Collectively, this work provides a uniform toolbox for ADC engineering and introduces new concepts for designing next-generation antibody conjugates with alternative payloads and mechanisms of action.","abstract_has_math":false,"creators":["Ringaci, Alina"],"institution":"Boston University","degree_name":"Doctor of Philosophy","degree_level":"doctoral","degree_discipline":"Chemistry","degree_department":null,"school":null,"contributors":[],"advisors":["Grinstaff, Mark W"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-19T02:42:12Z","subjects":["Chemistry","Biomedical engineering","Antibody-drug conjugates","Bioconjugation","Coiled-coil"],"languages":["en_US"],"rights":["Attribution 4.0 International"],"rights_urls":["http://creativecommons.org/licenses/by/4.0/"],"identifier_entries":[],"person_identifier_entries":[{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0001-6951-4032"],"render_values":[{"text":"0000-0001-6951-4032","href":"https://orcid.org/0000-0001-6951-4032","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2144/53607","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/53607","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F53607","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Grinstaff, Mark W"]},{"key":"dc:creator","label":"Author","values":["Ringaci, Alina"]},{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0001-6951-4032"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-10-05T18:06:48Z"]},{"key":"dc:date.embargo","label":"Dc Date Embargo","values":["2028-10-02T00:00:00Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-10-02T22:15:30Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chemistry","Biomedical engineering","Antibody-drug conjugates","Bioconjugation","Coiled-coil"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution 4.0 International"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://creativecommons.org/licenses/by/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/53607"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2026"]},{"key":"dc:description.abstract","label":"Abstract","values":["Antibody-drug conjugates (ADCs) have revolutionized cancer treatment, yet significant challenges limit their therapeutic potential and hamper their advancement to first-line treatments. Traditional conjugation methods lack stability, site-specificity and spatial control, resulting in heterogeneous products with compromised pharmacokinetics, efficacy, and safety profiles. This thesis presents a platform for advancing ADC technology through developing a novel peptide-based conjugation strategy and expands it to diverse payloads to create safe next-generation therapeutics. We first developed a supramolecular assembly conjugation method based on coiled-coil peptides to generate a robust site-specific ADC. This approach affords modular conjugation of multiple payloads. An ADC created via this platform demonstrated efficacy in human ovarian cancer xenograft model. Next, we developed a gram-scale synthetic scheme of a multifunctional cathepsin B-responsive linker that facilitates controlled drug release from antibodies. This scheme is high-yielding and avoids chromatographic purification, providing a pure product at the gram scale. Building on the coiled-coil conjugation platform, we demonstrated its modularity by expanding beyond traditional cytotoxic payloads to create antibody-enzyme conjugates that leverage enzymatic activity for metastasis reduction. By conjugating DNase to a neutrophil targeting antibody, we ensured enzyme delivery to close proximity of neutrophil extracellular traps, thereby reducing lung metastatic burden in an orthotopic 4T1 metastatic breast cancer model. Finally, we introduced a \"smart\" ADC platform integrating tumor-targeting with novel Regulated Induced Proximity Targeting Chimeras (RIPTACs). This approach overcomes off-target toxicities by requiring both extracellular target recognition and intracellular target recognition, establishing safer, more selective antibody-based therapeutics. Collectively, this work provides a uniform toolbox for ADC engineering and introduces new concepts for designing next-generation antibody conjugates with alternative payloads and mechanisms of action."]},{"key":"dc:title","label":"Title","values":["A self-assembling coiled-coil peptide platform for antibody-targeted therapeutics"]}]}],"canonical_facts":{"dc:contributor.advisor":["Grinstaff, Mark W"],"dc:creator":["Ringaci, Alina"],"dc:date.accessioned":["2026-10-05T18:06:48Z"],"dc:date.embargo":["2028-10-02T00:00:00Z"],"dc:date.issued":["2026"],"dc:date.updated":["2026-10-02T22:15:30Z"],"dc:description":["2026"],"dc:description.abstract":["Antibody-drug conjugates (ADCs) have revolutionized cancer treatment, yet significant challenges limit their therapeutic potential and hamper their advancement to first-line treatments. Traditional conjugation methods lack stability, site-specificity and spatial control, resulting in heterogeneous products with compromised pharmacokinetics, efficacy, and safety profiles. This thesis presents a platform for advancing ADC technology through developing a novel peptide-based conjugation strategy and expands it to diverse payloads to create safe next-generation therapeutics. We first developed a supramolecular assembly conjugation method based on coiled-coil peptides to generate a robust site-specific ADC. This approach affords modular conjugation of multiple payloads. An ADC created via this platform demonstrated efficacy in human ovarian cancer xenograft model. Next, we developed a gram-scale synthetic scheme of a multifunctional cathepsin B-responsive linker that facilitates controlled drug release from antibodies. This scheme is high-yielding and avoids chromatographic purification, providing a pure product at the gram scale. Building on the coiled-coil conjugation platform, we demonstrated its modularity by expanding beyond traditional cytotoxic payloads to create antibody-enzyme conjugates that leverage enzymatic activity for metastasis reduction. By conjugating DNase to a neutrophil targeting antibody, we ensured enzyme delivery to close proximity of neutrophil extracellular traps, thereby reducing lung metastatic burden in an orthotopic 4T1 metastatic breast cancer model. Finally, we introduced a \"smart\" ADC platform integrating tumor-targeting with novel Regulated Induced Proximity Targeting Chimeras (RIPTACs). This approach overcomes off-target toxicities by requiring both extracellular target recognition and intracellular target recognition, establishing safer, more selective antibody-based therapeutics. Collectively, this work provides a uniform toolbox for ADC engineering and introduces new concepts for designing next-generation antibody conjugates with alternative payloads and mechanisms of action."],"dc:identifier.orcid":["0000-0001-6951-4032"],"dc:identifier.uri":["https://hdl.handle.net/2144/53607"],"dc:language.iso":["en_US"],"dc:rights":["Attribution 4.0 International"],"dc:rights.uri":["http://creativecommons.org/licenses/by/4.0/"],"dc:subject":["Chemistry","Biomedical engineering","Antibody-drug conjugates","Bioconjugation","Coiled-coil"],"dc:title":["A self-assembling coiled-coil peptide platform for antibody-targeted therapeutics"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Doctor of Philosophy"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-19T02:42:12Z"}